Andrew Tsai
Stock Analyst at Jefferies
(1.13)
# 3,780
Out of 5,072 analysts
27
Total ratings
36.36%
Success rate
-10.14%
Average return
Main Sectors:
Stocks Rated by Andrew Tsai
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MPLT MapLight Therapeutics | Initiates: Buy | $32 | $13.63 | +134.78% | 1 | Nov 21, 2025 | |
| ANRO Alto Neuroscience | Maintains: Buy | $15 → $25 | $13.85 | +80.51% | 2 | Nov 12, 2025 | |
| AVDL Avadel Pharmaceuticals | Downgrades: Hold | $22 → $20 | $21.49 | -6.93% | 1 | Oct 22, 2025 | |
| PRAX Praxis Precision Medicines | Maintains: Buy | $65 → $300 | $196.46 | +52.70% | 1 | Oct 16, 2025 | |
| AKRO Akero Therapeutics | Downgrades: Hold | $75 → $56 | $54.36 | +3.02% | 1 | Oct 9, 2025 | |
| BIIB Biogen | Initiates: Buy | $190 | $182.09 | +4.34% | 1 | Sep 25, 2025 | |
| SRPT Sarepta Therapeutics | Maintains: Buy | $40 → $35 | $21.34 | +64.01% | 3 | Jul 24, 2025 | |
| STOK Stoke Therapeutics | Initiates: Buy | $30 | $30.91 | -2.94% | 1 | Jul 18, 2025 | |
| BBIO BridgeBio Pharma | Initiates: Buy | $70 | $72.01 | -2.79% | 1 | Jul 14, 2025 | |
| RCKT Rocket Pharmaceuticals | Downgrades: Hold | $29 → $2.5 | $3.42 | -26.90% | 2 | May 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $200 | $151.50 | +32.01% | 1 | Apr 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $19 → $27 | $17.23 | +56.70% | 2 | Mar 19, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $3.5 → $13 | $4.50 | +188.89% | 2 | Sep 17, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $35 | $29.47 | +18.76% | 1 | Jul 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $0.2 → $15 | $4.90 | +206.12% | 2 | Dec 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Hold | $3 | $1.43 | +109.79% | 1 | Mar 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $320 → $30 | $4.54 | +561.01% | 2 | Jun 23, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $27 | $3.89 | +594.09% | 1 | Sep 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $16 → $23 | $44.72 | -48.57% | 1 | Jun 1, 2020 |
MapLight Therapeutics
Nov 21, 2025
Initiates: Buy
Price Target: $32
Current: $13.63
Upside: +134.78%
Alto Neuroscience
Nov 12, 2025
Maintains: Buy
Price Target: $15 → $25
Current: $13.85
Upside: +80.51%
Avadel Pharmaceuticals
Oct 22, 2025
Downgrades: Hold
Price Target: $22 → $20
Current: $21.49
Upside: -6.93%
Praxis Precision Medicines
Oct 16, 2025
Maintains: Buy
Price Target: $65 → $300
Current: $196.46
Upside: +52.70%
Akero Therapeutics
Oct 9, 2025
Downgrades: Hold
Price Target: $75 → $56
Current: $54.36
Upside: +3.02%
Biogen
Sep 25, 2025
Initiates: Buy
Price Target: $190
Current: $182.09
Upside: +4.34%
Sarepta Therapeutics
Jul 24, 2025
Maintains: Buy
Price Target: $40 → $35
Current: $21.34
Upside: +64.01%
Stoke Therapeutics
Jul 18, 2025
Initiates: Buy
Price Target: $30
Current: $30.91
Upside: -2.94%
BridgeBio Pharma
Jul 14, 2025
Initiates: Buy
Price Target: $70
Current: $72.01
Upside: -2.79%
Rocket Pharmaceuticals
May 28, 2025
Downgrades: Hold
Price Target: $29 → $2.5
Current: $3.42
Upside: -26.90%
Apr 7, 2025
Initiates: Buy
Price Target: $200
Current: $151.50
Upside: +32.01%
Mar 19, 2025
Maintains: Overweight
Price Target: $19 → $27
Current: $17.23
Upside: +56.70%
Sep 17, 2024
Upgrades: Buy
Price Target: $3.5 → $13
Current: $4.50
Upside: +188.89%
Jul 2, 2024
Initiates: Buy
Price Target: $35
Current: $29.47
Upside: +18.76%
Dec 7, 2023
Upgrades: Buy
Price Target: $0.2 → $15
Current: $4.90
Upside: +206.12%
Mar 7, 2023
Initiates: Hold
Price Target: $3
Current: $1.43
Upside: +109.79%
Jun 23, 2022
Downgrades: Hold
Price Target: $320 → $30
Current: $4.54
Upside: +561.01%
Sep 1, 2021
Initiates: Buy
Price Target: $27
Current: $3.89
Upside: +594.09%
Jun 1, 2020
Assumes: Buy
Price Target: $16 → $23
Current: $44.72
Upside: -48.57%